Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyVisceral SurgeryDiseasePeritoneal MesotheliomaSubgroupICD10C45.1MeSHMesothelioma, MalignantSequenceChemotherapyChemo-substanceCisplatinDoxorubicinChemo-substanceCisplatinDoxorubicinChemo-substanceCisplatinDoxorubicinChemo-substanceCisplatinDoxorubicinNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances5Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseintraoperativTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO)HepatotoxicityIncrease AminotransferasesLeukopeniaNephrotoxicityThrombocytopenia below 50 000/µl only studiesPublicationAuthorChicago Consensus Working GroupFeldman AGilani SDiseasePeritonealmesotheliomPeritonealmesotheliom, ECOG 0-2Peritonealmesotheliom, Karnofsky > 50OriginChicago Consensus Working GroupPeritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UKSurgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, MDProtocols in Revision 3 protocols foundProtocols under revision.HIPEC - Cisplatin 100, peritoneal mesothelioma (PID2776 V1.1)HIPEC - Cisplatin 250, Peritoneal Mesothelioma (PID2795 V1.1)HIPEC - Cisplatin 50 / Doxorubicin 15, peritoneal mesothelioma (PID2708 V1.0)
